Enterprise Value
782.2M
Cash
160.5M
Avg Qtr Burn
-21.11M
Short % of Float
4.87%
Insider Ownership
4.98%
Institutional Own.
63.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LUMRYZ (FT218) Details Solid tumor/s, Melanoma, Narcolepsy, Excessive daytime sleepiness, Cataplexy | Approved Update | |
LUMRYZ (FT218) Details Excessive daytime sleepiness, Narcolepsy | sNDA Submission |